These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 15541832)

  • 1. The data monitoring experience in the MOXCON trial.
    Pocock S; Wilhelmsen L; Dickstein K; Francis G; Wittes J
    Eur Heart J; 2004 Nov; 25(22):1974-8. PubMed ID: 15541832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON).
    Cohn JN; Pfeffer MA; Rouleau J; Sharpe N; Swedberg K; Straub M; Wiltse C; Wright TJ;
    Eur J Heart Fail; 2003 Oct; 5(5):659-67. PubMed ID: 14607206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Strength of accumulating evidence and data monitoring committee decision making.
    George SL; Freidlin B; Korn EL
    Stat Med; 2004 Sep; 23(17):2659-72. PubMed ID: 15316949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the Data and Safety Monitoring Committee (DSMC).
    Wilhelmsen L
    Stat Med; 2002 Oct; 21(19):2823-9. PubMed ID: 12325098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Futility approaches to interim monitoring by data monitoring committees.
    Demets DL
    Clin Trials; 2006; 3(6):522-9. PubMed ID: 17170036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Monitoring the safety of participants in randomised clinical trials: basis and methods].
    Tijssen JG
    Ned Tijdschr Geneeskd; 2008 Mar; 152(12):674-8. PubMed ID: 18438062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Managed Ventricular pacing versus VVI 40 Pacing (MVP) Trial: clinical background, rationale, design, and implementation.
    Sweeney MO; Ellenbogen KA; Miller EH; Sherfesee L; Sheldon T; Whellan D
    J Cardiovasc Electrophysiol; 2006 Dec; 17(12):1295-8. PubMed ID: 17081208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving outcomes with long-term "destination" therapy using left ventricular assist devices.
    Long JW; Healy AH; Rasmusson BY; Cowley CG; Nelson KE; Kfoury AG; Clayson SE; Reid BB; Moore SA; Blank DU; Renlund DG
    J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1353-60; discussion 1360-1. PubMed ID: 18544385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monitoring of clinical trials and interim analysis. 1. Monitoring committee].
    Boutitie F; Bellissant E; Blanchard J; Boissel JP; Cauquil J; Chauvin F; Derzko G; Ducruet T; Durrleman S; Girre JP
    Therapie; 1992; 47(4):345-9. PubMed ID: 1494799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The perindopril in elderly people with chronic heart failure (PEP-CHF) study.
    Cleland JG; Tendera M; Adamus J; Freemantle N; Polonski L; Taylor J;
    Eur Heart J; 2006 Oct; 27(19):2338-45. PubMed ID: 16963472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials.
    Anderson GL; Kooperberg C; Geller N; Rossouw JE; Pettinger M; Prentice RL
    Clin Trials; 2007; 4(3):207-17. PubMed ID: 17715246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary data release for randomized clinical trials of noninferiority: a new proposal.
    Korn EL; Hunsberger S; Freidlin B; Smith MA; Abrams JS
    J Clin Oncol; 2005 Aug; 23(24):5831-6. PubMed ID: 16027441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What information should a sponsor of a randomized trial receive during its conduct?
    Anand SS; Wittes J; Yusuf S
    Clin Trials; 2011 Dec; 8(6):716-9. PubMed ID: 22024103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of the data safety and monitoring board in an international trial.
    NIMH Collaborative HIV/STD Prevention Trial
    AIDS; 2007 Apr; 21 Suppl 2():S99-102. PubMed ID: 17413269
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials.
    Saha SA; Molnar J; Arora RR
    Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board.
    Wittes J; Barrett-Connor E; Braunwald E; Chesney M; Cohen HJ; Demets D; Dunn L; Dwyer J; Heaney RP; Vogel V; Walters L; Yusuf S
    Clin Trials; 2007; 4(3):218-34. PubMed ID: 17715247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.